Semaglutide studies
8,508 journal papers mention Semaglutide in the title or abstract. Here are the most cited, the latest, and a few facts about the literature.
Studies range from laboratory work to clinical trials. A paper listed here is not an endorsement and says nothing about whether Semaglutide is safe, effective or approved for any use.
- Papers
- 8,508
- 6,959 articles, 1,549 reviews
- Earliest paper
- 2004
- Most papers in 2026 (2,732)
- Open access
- 64%
- free to read somewhere
- Reviews
- 18%
- of all papers listed
What kind of studies
Of 5,834 papers in PubMed that mention Semaglutide in the title or abstract, by the study type PubMed records. Categories overlap, so they do not add up to the total.
- Randomized controlled trials313
- Other clinical trials32
- Meta-analyses and systematic reviews427
- Other reviews1,739
- Case reports312
- Animal studies only278
- Studies in humans3,314
Study types are tags assigned by publishers and PubMed indexers; very new papers are often not tagged yet, and a tag is not a quality rating. Retracted papers are excluded. Source: PubMed (NCBI).
Registered clinical studies
Studies on ClinicalTrials.gov that mention Semaglutide in their intervention details. A registration says a study is planned or running, not what it found.
- Registered
- 796
- Completed
- 353
- Ongoing or planned
- 373
- Phase 1
- 127
- Phase 2
- 153
- Phase 3
- 185
- Comparing Different Medication Regimens to Maintaining Weight Loss Among Adults With Obesity Using GLP-1s
NCT07832084Not yet recruitingPhase 4started 2026-12
- Focusing on the Menopausal Transition to Improve Mid-Life Women's Health
NCT06975111RecruitingPhase 2 / Phase 3started 2026-03-01
- Brain and Obesity Longitudinal Development: Neurobiological Mechanisms of Semaglutide Treatment of Adolescent Obesity
NCT07911046Not yet recruitingstarted 2027-03
- Research Study to Look at How Well Semaglutide Works in People Living With Heart Failure, Obesity and Type 2 Diabetes
NCT04916470CompletedPhase 3started 2021-06-15
- Changes in Body Composition Following Pharmacological Treatment for Obesity.
NCT07908940Enrolling by invitationstarted 2025-09-01
The five most recently updated studies. See all 796 on ClinicalTrials.gov. Source: ClinicalTrials.gov (U.S. National Library of Medicine). Studies are found by the compound's name, so a few may be about something else.
Papers per year
2004 to 2026, peak 2,732 papers in a year. The latest year may still be incomplete.
Where it is published
- Diabetes492 papers
- Diabetes Obesity and Metabolism358 papers
- Cureus164 papers
- European Heart Journal158 papers
- Journal of the Endocrine Society117 papers
The papers
Most citedName in the title
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Steven P. Marso, Stephen Charles Bain, Agostino Consoli et al. · New England Journal of Medicine · 2016
Randomized trialOpen access6,903 citationsRead the open copy →
- Once-Weekly Semaglutide in Adults with Overweight or Obesity
John P.H. Wilding, Rachel Louise Batterham, Salvatore Calanna et al. · New England Journal of Medicine · 2021
Randomized trialOpen access5,217 citationsRead the open copy →
- Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Abraham Michael Lincoff, Kirstine Brown‐Frandsen, Helen Martina Colhoun et al. · New England Journal of Medicine · 2023
Randomized trialOpen access3,240 citationsRead the open copy →
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Juan P. Frías, Melanie Jane Davies, Julio Rosenstock et al. · New England Journal of Medicine · 2021
Randomized trial · Phase 3Open access · CC BY2,099 citationsRead the open copy →
- A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis
Philip Noel Newsome, Kristine Buchholtz, Kenneth J. Cusi et al. · New England Journal of Medicine · 2020
Randomized trial · Phase 2Open access2,043 citationsRead the open copy →
- Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Mansoor Husain, Andreas L. Birkenfeld, Morten Donsmark et al. · New England Journal of Medicine · 2019
Open access1,997 citationsRead the open copy →
- Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes
Vlado Perkovic, Katherine R. Tuttle, Peter R Rossing et al. · New England Journal of Medicine · 2024
Randomized trial1,945 citations
- Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity
Mikhail Kosiborod, Steen Zabell Abildstrom, Barry A. Borlaug et al. · New England Journal of Medicine · 2023
Randomized trialOpen access1,670 citationsRead the open copy →
- Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity
Domenica Rubino, Niclas Abrahamsson, Melanie Jane Davies et al. · JAMA · 2021
Randomized trial · Phase 3Open access1,448 citationsRead the open copy →
- Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial
Melanie Jane Davies, Louise Færch, Ole Kleist Jeppesen et al. · The Lancet · 2021
Randomized trial · Phase 3Open access · CC BY-NC-ND1,420 citationsRead the open copy →
- Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension
John P.H. Wilding, Rachel Louise Batterham, Melanie Jane Davies et al. · Diabetes Obesity and Metabolism · 2022
Randomized trialOpen access · CC BY1,129 citationsRead the open copy →
- Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis
Arun Jayant Sanyal, Philip Noel Newsome, Iris Kliers et al. · New England Journal of Medicine · 2025
Randomized trial · Phase 3Open access1,123 citationsRead the open copy →
- Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity
Thomas A. Wadden, Timothy Silleck Bailey, Liana K. Billings et al. · JAMA · 2021
Randomized trial · Phase 3Open access1,115 citationsRead the open copy →
- Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide
Jesper F. Lau, Paw Bloch, Lauge Schäffer et al. · Journal of Medicinal Chemistry · 2015
Study in humans1,106 citations
- Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes
Domenica M. Rubino, Frank L. Greenway, Usman Khalid et al. · JAMA · 2022
Randomized trial · Phase 3Open access997 citationsRead the open copy →
- The Discovery and Development of Liraglutide and Semaglutide
Lotte Bjerre Knudsen, Jesper F. Lau · Frontiers in Endocrinology · 2019
ReviewOpen access · CC BY971 citationsRead the open copy →
- Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial
William Timothy Garvey, Rachel Louise Batterham, Meena Bhatta et al. · Nature Medicine · 2022
Randomized trialOpen access · CC BY870 citationsRead the open copy →
- Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial
Patrick Mahlen O'Neil, Andreas L. Birkenfeld, Barbara M. McGowan et al. · The Lancet · 2018
Randomized trial · Phase 2814 citations
- Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial
Richard E. Pratley, Vanita R. Aroda, Ildiko Lingvay et al. · The Lancet Diabetes & Endocrinology · 2018
Randomized trial · Phase 3791 citations
- Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes
Mikhail Kosiborod, Mark Colquhoun Petrie, Barry A. Borlaug et al. · New England Journal of Medicine · 2024
Randomized trialOpen access758 citationsRead the open copy →
- Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial
CHRISTOPHER H. SORLI, Shin‐ichi Harashima, George M. Tsoukas et al. · The Lancet Diabetes & Endocrinology · 2017
Randomized trial · Phase 3746 citations
- Once-Weekly Semaglutide in Adolescents with Obesity
Daniel Weghuber, Timothy Geoffrey Barrett, Margarita Barrientos Pérez et al. · New England Journal of Medicine · 2022
Randomized trialOpen access730 citationsRead the open copy →
- Semaglutide lowers body weight in rodents via distributed neural pathways
Sanaz Gabery, Casper Graversen Salinas, Sarah Juel Paulsen et al. · JCI Insight · 2020
Animal studyOpen access · CC BY721 citationsRead the open copy →
- Effects of once‐weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity
John Edward Blundell, Graham Finlayson, Mads Buhl Axelsen et al. · Diabetes Obesity and Metabolism · 2017
Randomized trialOpen access · CC BY-NC-ND693 citationsRead the open copy →
- Tirzepatide as Compared with Semaglutide for the Treatment of Obesity
Louis J. Aronne, Deborah Bade Horn, Carel Wynand le Roux et al. · New England Journal of Medicine · 2025
Clinical trial · Phase 3Open access · CC BY-NC-ND635 citationsRead the open copy →
- Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial
Andrew Ahmann, Matthew Capehorn, Guillaume Charpentier et al. · Diabetes Care · 2017
Randomized trial · Phase 3597 citations
- Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial
Richard E. Pratley, Aslam Amod, Soren Tetens Hoff et al. · The Lancet · 2019
Randomized trial · Phase 3595 citations
- Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial
Rohit Seth Loomba, Manal F. Abdelmalek, Matthew James Armstrong et al. · The Lancet. Gastroenterology & hepatology · 2023
Randomized trial · Phase 2Open access · CC BY-NC-ND533 citationsRead the open copy →
- The GLP-1 Analogs Liraglutide and Semaglutide Reduce Atherosclerosis in ApoE−/− and LDLr−/− Mice by a Mechanism That Includes Inflammatory Pathways
Günaj Rakipovski, Bidda Charlotte Rolin, Jane Nøhr et al. · JACC Basic to Translational Science · 2018
Open access · CC BY-NC-ND509 citationsRead the open copy →
- Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes
Melanie Jane Davies, Thomas Rudolf Pieber, Marie‐Louise Hartoft‐Nielsen et al. · JAMA · 2017
Randomized trial · Phase 2Open access506 citationsRead the open copy →
- Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial
Bo Åhrén, Lluís Masmiquel, Harish Kumar et al. · The Lancet Diabetes & Endocrinology · 2017
Randomized trial · Phase 3496 citations
- PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes
Vanita R. Aroda, Julio Rosenstock, Yasuo Terauchi et al. · Diabetes Care · 2019
Study in humansOpen access494 citationsRead the open copy →
- Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial
Helena W. Rodbard, Julio Rosenstock, Luís Henrique Santos Canani et al. · Diabetes Care · 2019
Randomized trialOpen access464 citationsRead the open copy →
- Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial
Vanita R. Aroda, Stephen Charles Bain, Bertrand Cariou et al. · The Lancet Diabetes & Endocrinology · 2017
Randomized trial · Phase 3464 citations
- Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis
Henning Bliddal, Harold Edward Bays, Sébastien Czernichow et al. · New England Journal of Medicine · 2024
Randomized trial · Phase 3441 citations
- Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial
Filip Krag Knop, Vanita R. Aroda, Ruben Duque do Vale et al. · The Lancet · 2023
Randomized trial · Phase 3434 citations
- The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity
Martin Haljeta Friedrichsen, Astrid Breitschaft, Sayeh Tadayon et al. · Diabetes Obesity and Metabolism · 2020
Randomized trialOpen access · CC BY-NC429 citationsRead the open copy →
- Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With Sulfonylurea
Julio Rosenstock, Dale Allison, Andreas L. Birkenfeld et al. · JAMA · 2019
Randomized trial · Phase 3Open access421 citationsRead the open copy →
- Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes
Darren K. McGuire, Nikolaus Marx, Sharon L. Mulvagh et al. · New England Journal of Medicine · 2025
Randomized trialOpen access417 citationsRead the open copy →
- Efficacy and safety of once-weekly semaglutide 1.0 mg vs once-daily liraglutide 1.2 mg as add-on to 1–3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10)
Matthew Capehorn, Andrei‐Mircea Catarig, Julie Kjærulff Furberg et al. · Diabetes & Metabolism · 2019
Randomized trial · Phase 3412 citations
LatestName in title or abstract
- GLP-1 Receptor Agonists Versus Empagliflozin or Dapagliflozin in the MASLD-Heart Failure Phenotype: An Exploratory Propensity-Matched Cohort Study
Naveen Gautam, Tien Manh Huynh, Hong Hieu Truong et al. · Balkan Medical Journal · 2026
Open access · CC BY-NC-NDRead the open copy →
- Childhood Obesity And Incretin Therapies With GLP-1 And GIP Receptor Agonists: Efficacy, Safety, And Prospects For Semaglutide And Tirzepatide In Children And Adolescents
Larissa Lauretto, VITOR DACIO MEDEIROS, Vitória de Almeida Rolim Rabelo et al. · Journal of diabetology research. · 2026
Open access · CC BYRead the open copy →
- Potential synergy between GLP-1 receptor agonists and follicle-stimulating hormone in improving spermatogenesis: biological rationale and future directions
Sandro La Vignera, Aldo Eugenio Calogero, Rossella Cannarella et al. · Frontiers in Endocrinology · 2026
Open access · CC BYRead the open copy →
- Therapeutic silencing of serine/threonine kinase 25 for obesity-associated MASLD
Daniel Ferguson, Robert Nathaniel Helsley · Molecular Therapy — Nucleic Acids · 2026
Open access · CC BYRead the open copy →
- Semaglutide and Cardiovascular Death: a Systematic Review and Meta-Analysis Cardioprotective Efficacy of Semaglutide
G. Marino, Stefano Aquilani, Stefania Angela Di Fusco et al. · Critical Pathways in Cardiology A Journal of Evidence-Based Medicine · 2026
- Rapid oral desensitization to semaglutide following anaphylaxis with positive intradermal testing
Natalhie Acuña-Ortega, Sandra Nora González Díaz, Marcela Villalobos Ordaz et al. · Allergologia et Immunopathologia · 2026
Open accessRead the open copy →
- Efficacy and safety of semaglutide versus placebo in adults with overweight or obesity without diabetes: updated meta-analysis of randomized trials
Rida Wajid, Ravi Kumar, Misbah Muneer et al. · Journal of Diabetes & Metabolic Disorders · 2026
Review
- A Novel Salcaprozate Sodium Deep Eutectic System for Oral Semaglutide Delivery and Enhanced Skin Penetration
Jiawen Chen, Keting Chen, Ting Wang et al. · Pharmaceutics · 2026
Open access · CC BYRead the open copy →
- Advances in the non-invasive assessment of metabolic dysfunction-associated steatotic liver disease
Ningrui Su, Da Zhou, Jiangao Fan · Metabolism and Target Organ Damage · 2026
Open access · CC BYRead the open copy →
- Cardiovascular and Cerebrovascular Outcomes Risk Reduction Associated With Semaglutide vs Tirzepatide
顏江河, Guangting Zeng · JACC Advances · 2026
Open access · CC BYRead the open copy →
- Community awareness and misconceptions regarding GLP-1 receptor agonists for weight management among adults in the Aseer Region, Saudi Arabia: a cross-sectional study
Asma M. Alshahrani, Geetha Kandasamy, Sitah Alharthi et al. · Frontiers in Public Health · 2026
Open access · CC BYRead the open copy →
- Glucagon-Like Peptide-1 Analog–Type Amyloidosis: A Case Report and Review of the Literature
John Loggie, Robert C. McKay, Samih H. Nasr et al. · American Journal of Dermatopathology · 2026
- Analysis Asks: Are GLP-1 Drugs Safe in People With Frailty?
Anna Bock · JAMA · 2026
- EMERGING PHARMACOLOGICAL STRATEGIES IN OBESITY: FROM GLP-1 AGONISTS THROUGH TRIPLE INCRETIN THERAPY TO AMYLIN ANALOGS – NARRATIVE REVIEW
Dagmara Laufer, Olga Klimczak, Filip Chodań et al. · Archiv Euromedica · 2026
ReviewOpen accessRead the open copy →
- Specialist Perspectives on West Virginia Medicaid Coverage Requirements for Semaglutide: A Qualitative Study of Perceived Barriers in a Rural State
Yongjia Deng, Katherine Shepherd, Kanith Farah et al. · Marshall Journal of Medicine · 2026
Open access · CC BYRead the open copy →
- Comparative adverse-event reporting patterns of semaglutide and tirzepatide: a disproportionality analysis of FAERS
Turgay Arslan · Endocrine · 2026
Study in humans
- Early Treatment Trajectory and Long‐Term Persistence to Semaglutide for Obesity: A Population‐Based Cohort Study
Eitan Winter, Yael Wolff Sagy, Orna Reges et al. · Diabetes Obesity and Metabolism · 2026
Open accessRead the open copy →
- Changes in Sexual Function and Sexual Quality of Life During GLP-1–Based Therapy in Premenopausal Women with Obesity
Hazel Demiröz Öztürk, Yusuf Öztürk · Medicina · 2026
Open access · CC BYRead the open copy →
- Switching between semaglutide and tirzepatide in obesity Management: an expert-consensus framework for approximate clinical Efficacy-matched switching doses
Eyal Schwartzberg, Erez Berman, Segev Shani et al. · Expert Opinion on Pharmacotherapy · 2026
ReviewOpen access · CC BY-NC-NDRead the open copy →
- Semaglutide versus other GLP-1 RAs and cardiovascular risk in obesity-related cancer survivors
Omer Abdelgadir, Jesús Gibran Hernández‐Pérez, Maryam R. Hussain et al. · Diabetes Research and Clinical Practice · 2026
- Tirzepatide Versus Semaglutide in Heart Failure With Preserved Ejection Fraction and Type 2 Diabetes: A Target Trial Emulation Study
John W. Ostrominski, Janinne Ortega-Montiel, Wajd Alkabbani et al. · Diabetes Obesity and Cardiometabolic CARE · 2026
- Comparative Effects of Pharmacological Treatment on Heart Failure with Mildly Reduced or Preserved Ejection Fraction: A Systematic Review and Network Meta-analysis of Randomized Controlled Trials
Jingyi Zhang, 王永健, Jinjin Li et al. · Drugs · 2026
Systematic review
- Anatomical and Molecular Foundations of the Gut–Brain Axis in Alzheimer’s Disease: From Molecular Mechanisms to Therapeutic Translation
Bhagath Kumar Potu, Abirami Arulkandan, Prarthana Kalerammana Gopalakrishna et al. · Nutrients · 2026
Open access · CC BYRead the open copy →
- Comparação entre Tirzepatida e Semaglutida na redução de peso em pacientes adultos com obesidade: uma revisão integrativa da literatura
Karine Thamires Witt, Antônio Carlos Mattar Munhoz, Isabela Hoefel Martins et al. · Revista de Medicina UNC · 2026
Open access · CC BY-NDRead the open copy →
- Semaglutide Exposure and Risk of Oral Mucositis, Systemic Complications, and Mortality Among Patients with a History of Hematopoietic Stem-Cell Transplantation: A Propensity-Matched Real-World Cohort Study
Zak Ahmed, Kiera Kavcic, Joel Epstein et al. · Clinics and Practice · 2026
Open access · CC BYRead the open copy →
- Primary progressive dementia in 2026: beyond amyloid, towards biomarker-guided and equitable care. A viewpoint from Croatia and resource-constrained health systems
Anđelko Vrca · Journal of Global Health Neurology and Psychiatry · 2026
Open access · CC BYRead the open copy →
- GLP‐1 receptor activation attenuates chronic migraine‐like behaviour: Sex‐specific modulation of opioid‐ and endocannabinoid‐related pathways
Katarina Sićović, Katarina Nastić, Miroslav Dinić et al. · British Journal of Pharmacology · 2026
Open access · CC BYRead the open copy →
- AI-enabled drug repurposing in Alzheimer’s disease: from computational nomination to pharmacological proof
Xinzhong Li, Illana Gozes · Frontiers in Pharmacology · 2026
Open access · CC BYRead the open copy →
- Gut Delivery of Pentameric GLP-1 Using Genetically Engineered Bacillus subtilis
Ningyuan Ye, Francesco Di Pierro, Nicola Zerbinati et al. · ACS Synthetic Biology · 2026
Open access · CC BY-NC-ND1 citationsRead the open copy →
- Beyond glycemic control: ocular effects of GLP-1 receptor agonists across medical and surgical ophthalmology
Alexa Crystal González Herrera, Agustín Bastida Beiza, Dalia Azucena de Luna Vega et al. · International Surgery Journal · 2026
Open access · CC BY-NC-NDRead the open copy →
- Efficacy and Safety of CagriSema in Type 2 Diabetes: A Dose‐ and Comparator‐Specific Systematic Review and Bayesian Meta‐Analysis
Chia Siang Kow, Abdullah Faiz Zaihan, Dinesh Sangarran Ramachandram et al. · Diabetes Obesity and Metabolism · 2026
ReviewOpen access · CC BYRead the open copy →
- Semaglutide and Panic Attacks: Active‐Comparator Disproportionality Analysis, Temporal Assessment of Notoriety Bias and Evidence Triangulation in Post‐Marketing Pharmacovigilance
Ben Melamed, Mahak Parsi‐Zahabi, Mohammad Ali Omrani et al. · Pharmacoepidemiology and Drug Safety · 2026
Study in humansOpen access · CC BYRead the open copy →
- Oral Health–Related Adverse Events of GLP-1 Receptor Agonists
F.C. Massarotto, A.H. Mahmoud, G.E. Watson et al. · JDR Clinical & Translational Research · 2026
Open accessRead the open copy →
- Glucagon-like Peptide-1 Receptor Agonists in Heart Transplant Recipients With Type 2 Diabetes: A Multicenter Study
Zorba Blázquez‐Bermejo, Daniel Enríquez-Vázquez, Elena García‐Romero et al. · Transplantation · 2026
- Predicting response to GLP-1–based therapy in MASLD/MASH: an evidence-tiered, endpoint-specific framework built on host genotype and gut microbial features
Guojian Zhu, Yucao Huang, Yun Huang et al. · Frontiers in Endocrinology · 2026
Open access · CC BYRead the open copy →
- Target Trial of Semaglutide Versus Dulaglutide or Liraglutide in Patients Receiving Hemodialysis
Dustin Le, Evan Forman, Walter K. Kraft et al. · Diabetes Care · 2026
- What Is the Role of GLP-1 Receptor Agonists in the Treatment of MASLD: A Narrative Review
Sweera A. Qari, Kay Samuel, Jonathan Andrew Fallowfield et al. · Livers · 2026
ReviewOpen access · CC BYRead the open copy →
- GLP‐1–Based Therapy in Type 1 Diabetes: Balancing Efficacy, Safety, and Patient Selection
Thales Rossatto, Ricardo de Andrade Oliveira, Andréia Machado Cardoso · Diabetes Obesity and Metabolism · 2026
ReviewOpen access · CC BYRead the open copy →
- GLP-1 receptor agonist–associated weight loss in breast cancer patients receiving concurrent endocrine therapy: a retrospective cohort analysis
Keri Morgan Cronin, Amy Tiersten · Breast Cancer Research and Treatment · 2026
Study in humans
- Beyond glycemic control: emerging therapeutic applications of GLP-1 receptor agonists: a comprehensive narrative review
Nidhi Srivastava, Siddhant Mehrotra, Shubham Biswas et al. · International Journal of Basic & Clinical Pharmacology · 2026
ReviewOpen access · CC BY-NC-NDRead the open copy →
Each list shows up to 40 papers.See all 8,508 on OpenAlex. Source: OpenAlex (CC0), journal articles and reviews with a DOI, retractions excluded, refreshed weekly, last 4 Nov 2026, 08:31 UTC. Papers are listed by their metadata only; follow the links to read them. A license shown on an open copy is the license the publisher or repository states for that copy.